[
1. Abdelrahman A, Hasan E, Abdelgawad S, Sallam M. Acute myeloid leukemia, M1 with trisomy 1, 8, and 21: a case report of a rare complex karyotype. Egypt. J. Haematol. 2016;41(2):106.
]Search in Google Scholar
[
2. Amanollahi Kamaneh E, Shams Asenjan K, Movassaghpour Akbari A et al. Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran. Cell Journal (Yakhteh). 2016;18(1).
]Search in Google Scholar
[
3. Wang M, Yang C, Zhang L, Schaar DG. Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia. Stem Cells Int. 2017;2017:6962379.
]Search in Google Scholar
[
4. Stölzel F, Mohr B, Kramer M et al. Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer Journal. 2016;6(1):e386.
]Search in Google Scholar
[
5. Karam Al-Issa AN. Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biol. Med. 2016;13(4):474.
]Search in Google Scholar
[
6. Rubio P, Campos B, Digiorge J et al. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value. Int. J. Hematol. 2016;104(5):582-90.
]Search in Google Scholar
[
7. Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms. J. Mol. Diagn. 2015;17(1):76-84.
]Search in Google Scholar
[
8. Su L, Gao S, Liu X et al. CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a chinese population. Onco Targets Ther. 2016;9:3399.
]Search in Google Scholar
[
9. Allahyari A, Sadeghi M, Ayatollahi H et al. Frequency of FLT3 (ITD, D835) Gene Mutations in Acute Myelogenous Leukemia: a Report from Northeastern Iran. APJCP. 2016; 17(9):4319-22.
]Search in Google Scholar
[
10. Byun JM, Kim YJ, Yoon H-J et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia – a retrospective multicenter nationwide study. Ann. Hematol. 2016;95(8):1223-32.
]Search in Google Scholar
[
11. He R, Wiktor AE, Hanson CA et al. Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. Am. J. Clin. Pathol. 2015;143(6):873-8.
]Search in Google Scholar
[
12. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? ASH Education Program Book. 2013;2013(1):220-6.
]Search in Google Scholar
[
13. Amare PK, Jain H, Kabre S et al. Cytogenetic Profile in 7209 Indian Patients with de novo Acute Leukemia: A Single Centre Study from India. J. Cancer Therapy. 2016;7(07):530.
]Search in Google Scholar
[
14. Komanduri KV, Levine RL. Diagnosis and therapy of acute myeloid leukemia in the era of molecular risk stratification. Annual review of medicine. 2016;67:59-72.
]Search in Google Scholar
[
15. Papaemmanuil E, Gerstung M, Bullinger L et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-21.
]Search in Google Scholar
[
16. Creutzig U, Zimmermann M, Reinhardt D et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821-30.
]Search in Google Scholar
[
17. Wakita S, Yamaguchi H, Ueki T et al. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia. 2016;30(3):545.
]Search in Google Scholar
[
18. How J, Sykes J, Minden M et al. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. Blood cancer journal. 2013;3(5):e116.
]Search in Google Scholar
[
19. Chauhan PS, Ihsan R, Singh L et al. Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. Disease markers. 2013;35(5):581-8.
]Search in Google Scholar
[
20. Falini B, Mecucci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-66.
]Search in Google Scholar
[
21. Byrd JC, Mrózek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36.
]Search in Google Scholar
[
22. Master S, Mansour R, Devarakonda SS et al. Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality. Anticancer research. 2016;36(4):1719-27.
]Search in Google Scholar
[
23. Ashrafi F, Shahnazari R, Samimi MA, Mehrzad V. Results of treatment of acute myeloid leukemia in central part of Iran. Adv. Biomed. Res. 2013;2.
]Search in Google Scholar
[
24. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
]Search in Google Scholar
[
25. Roukos V, Misteli T. The biogenesis of chromosome translocations. Nat. Cell Biol. 2014;16(4):293.
]Search in Google Scholar
[
26. Chung NG, Buxhofer-Ausch V, Radich J. The detection and significance of minimal residual disease in acute and chronic leukemia. HLA. 2006;68(5):371-85.
]Search in Google Scholar
[
27. Campo E, Swerdlow SH, Harris NL et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-32.
]Search in Google Scholar
[
28. Mrózek K, Marcucci G, Nicolet D et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J. Clin. Oncol. 2012;30(36):4515-23.
]Search in Google Scholar
[
29. Ayatollahi H, Sadeghian MH, Naderi M et al. Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2017;22.
]Search in Google Scholar
[
30. Brown P, McIntyre E, Rau R et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110(3):979-85.
]Search in Google Scholar
[
31. Cazzaniga G, Dell’Oro MG, Mecucci C et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106(4):1419-22.
]Search in Google Scholar
[
32. Braoudaki M, Papathanassiou C, Katsibardi K et al. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J. Hematol Oncology. 2010;3(1):41.
]Search in Google Scholar
[
33. Schneider F, Hoster E, Schneider S et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann. Hematol. 2012;91(1):9-18.
]Search in Google Scholar